Mary Wilson
Well-known member
Open Access
Published: October 05, 2020
DOI:https://doi.org/10.1016/S0140-6736(20)32013-4
Summary
Background
Lopinavir–ritonavir has been proposed as a treatment for COVID-19 on the basis of in vitro activity, preclinical studies, and observational studies. Here, we report the results of a randomised trial to assess whether lopinavir–ritonavir improves outcomes in patients admitted to hospital with COVID-19.
Methods
In this randomised, controlled, open-label, platform trial, a range of possible treatments was compared with usual care in patients admitted to hospital with COVID-19. The trial is underway at 176 hospitals in the UK.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32013-4/fulltext
Published: October 05, 2020
DOI:https://doi.org/10.1016/S0140-6736(20)32013-4
Summary
Background
Lopinavir–ritonavir has been proposed as a treatment for COVID-19 on the basis of in vitro activity, preclinical studies, and observational studies. Here, we report the results of a randomised trial to assess whether lopinavir–ritonavir improves outcomes in patients admitted to hospital with COVID-19.
Methods
In this randomised, controlled, open-label, platform trial, a range of possible treatments was compared with usual care in patients admitted to hospital with COVID-19. The trial is underway at 176 hospitals in the UK.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32013-4/fulltext